Cancer

Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA non-small cell lung cancer and stage III colon cancer

European collaboration demonstrates the value of targeted tumor analysis

OHSU researchers identified new drug combination that could overcome treatment resistance in acute myeloid leukemia

The test leverages cellular biophysics and machine learning to offer a high-sensitivity alternative to traditional urine-based assays

If 2024 was defined by the looming threat of the FDA's "Final Rule" on laboratory-developed tests (LDTs), 2025 was defined by its sudden dismantling

Roche’s PATHWAY HER2 (4B5) test is the only test approved to identify all levels of HER2 expression

More than 30 new drugs have been approved for pediatric cancer in the past 10 years, but progress has not benefited all patients

AI-powered, multilingual cancer research pipeline will accelerate the pace of global data curation and expand access to real-world clinical data

As liquid biopsy becomes a standard tool in oncology, distinguishing tumor signals from clonal hematopoiesis is essential for accurate results

Detecting all PML-RARA fusion isoforms in a single assay could help simplify the diagnostic workflow for acute promyelocytic leukemia

Long-term data show PSA screening lowers prostate cancer deaths but underscores risks of overdiagnosis

Newly identified F2R receptor shows promise for earlier detection and improved treatment outcomes

Scientific review discusses how new advances in 3D bioprinting, organoids, organs-on-a-chip aid in the fight against cancer

New findings show that specific p53 variants, such as R273H, may predict stronger responses to immune checkpoint inhibitors

State of Lung Cancer 2025 identifies lessons from Delaware and other states to expand screening, increase biomarker testing coverage, and save lives

Results highlight the importance of routine cancer screenings, suggest genetic testing should go beyond high-risk groups

This is especially crucial for patients with treatment-resistant cancers and those with triple-negative breast cancer

With a little help, your immune cells can be potent tumor killers

Epigenetic editors create enhanced T cells that show improved survival in cancer models, without the risk of DNA damage

Building on previous research, the observation also marks a significant step toward a long-awaited universal cancer vaccine